Focus: BlueRock Therapeutics is a Berlin-based biotech company specializing in stem cell therapies, with a focused pipeline in cell therapy for neurodegenerative and retinal diseases. The company operates as a pre-revenue or early-stage biotech entity with limited disclosed financial scale.
Profile data last refreshed 4h ago · AI intelligence enriched 2mo ago
Growing — net +8 jobs in 30d
11 jobs added vs 3 removed. Steady team buildout.
BlueRock presents a high-risk, high-reward career opportunity suited for scientists and developers willing to bet on early-stage cell therapy innovation with uncertain financial backing.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for BlueRock Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from BlueRock Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles